EUVIMEDEUVIMED entdecken
Open Access

RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons

Diya Surie, Wesley H Self, Katharine A Yuengling, Adam S Lauring, Yuwei Zhu, Basmah Safdar, Adit A Ginde, Samantha J Simon, Ithan D Peltan, Samuel M Brown, Manjusha Gaglani, Shekhar Ghamande und 38 weitere

JAMA · 28.10.2025 · 334 (16) · 1442

DOI: 10.1001/jama.2025.15896 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 28.10.2025. Verfasst von Diya Surie und 49 weiteren Autor:innen. Beteiligte Einrichtung: Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preven…. Hauptthemen laut MEDLINE: Hospitalization, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Vaccine Efficacy. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Respiratory syncytial virus (RSV) vaccines for adults aged 60 years or older became available in 2023. One dose is recommended for all adults aged 75 years or older and those aged 60 to 74 years at increased risk of severe RSV; however, duration of protection is unknown.

Objective

To evaluate RSV vaccine effectiveness against RSV-associated hospitalization among adults aged 60 years or older during 2 RSV seasons. Design, Setting, and Participants A total of 6958 adults aged 60 years or older were included in this test-negative, case-control study if they were hospitalized with acute respiratory illness at any of 26 hospitals in 20 US states during the October 1, 2023, to March 31, 2024, or October 1, 2024, to April 30, 2025, RSV seasons and had respiratory virus testing within 10 days of illness onset. Case patients tested positive for RSV only; control patients tested negative for RSV, SARS-CoV-2, and influenza. Demographic and clinical data were obtained through patient interview and electronic health records. Exposures Receipt of 1 RSV vaccine dose at least 14 days before illness onset. Main Outcomes and Measures Multivariable logistic regression was used to compare the odds of RSV vaccination among hospitalized cases and controls. Models were adjusted for age, sex, race and ethnicity, geographic region, and calendar month and year. Vaccine effectiveness was estimated as (1 – adjusted odds ratio) × 100%. Analyses were stratified by timing of RSV vaccine receipt (same vs prior season) relative to illness onset.

Results

Of 6958 adults aged 60 years or older, 821 (11.8%) were RSV cases and 6137 (88.2%) were controls. A total of 1438 patients were Black (20.1%) and 4314 were White (62.0%); 3534 were female (50.8%). Median age was 72 years (IQR, 66-80 years) and 1829 adults (26.3%) were immunocompromised. A total of 63 cases (7.7%) and 966 controls (15.7%) were vaccinated. Estimated vaccine effectiveness against RSV-associated hospitalization was 58% (95% CI, 45%-68%) during 2 seasons and 69% (95% CI, 52%-81%) for same-season vaccination vs 48% (95% CI, 27%-63%; P = .06) for prior-season vaccination. Estimated vaccine effectiveness during 2 seasons was significantly lower among immunocompromised adults (30%; 95% CI, −9% to 55%) than immunocompetent adults (67%; 95% CI, 53%-77%; P = .02) and among those with cardiovascular disease (56%; 95% CI, 32%-72%) vs without (80%; 95% CI, 62%-90%; P = .03). Conclusions and Relevance Respiratory syncytial virus vaccines prevented RSV-associated hospitalization during 2 seasons, although effectiveness was lower in patients with immunocompromise and cardiovascular disease than in those without these conditions. Ongoing monitoring is needed to determine the optimal RSV revaccination interval.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HospitalizationRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesVaccine EfficacyAgedAged, 80 and overFemaleHumansMaleMiddle AgedCase-Control StudiesSeasonsUnited StatesImmunization ScheduleAge FactorsVaccinationRespiratory Syncytial VirusesTreatment Outcome

Substanzen

Respiratory Syncytial Virus Vaccines

Autor:innen und Institutionen

  • Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.
  • Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Department of Internal Medicine, University of Michigan, Ann Arbor.
  • Department of Microbiology and Immunology, University of Michigan, Ann Arbor.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Surie, D., Self, W. H., Yuengling, K. A., Lauring, A. S., Zhu, Y., Safdar, B., Ginde, A. A., Simon, S. J., Peltan, I. D., Brown, S. M., Gaglani, M., Ghamande, S., Columbus, C., Mohr, N. M., Gibbs, K. W., Hager, D. N., Prekker, M., Gong, M. N., Mohamed, A., …, & Investigating Respiratory Viruses in the Acutely Ill (IVY) Network (2025). RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons. JAMA, 334(16), 1442. https://doi.org/10.1001/jama.2025.15896

Vancouver

Surie D, Self WH, Yuengling KA, Lauring AS, Zhu Y, Safdar B, et al. RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons. JAMA. 2025;334(16):1442. doi:10.1001/jama.2025.15896

BibTeX
@article{Surie2025,
  author = {Surie, Diya and Self, Wesley H and Yuengling, Katharine A and Lauring, Adam S and Zhu, Yuwei and Safdar, Basmah and Ginde, Adit A and Simon, Samantha J and Peltan, Ithan D and Brown, Samuel M and Gaglani, Manjusha and Ghamande, Shekhar and Columbus, Cristie and Mohr, Nicholas M and Gibbs, Kevin W and Hager, David N and Prekker, Matthew and Gong, Michelle N and Mohamed, Amira and Johnson, Nicholas J and Steingrub, Jay S and Khan, Akram and Duggal, Abhijit and Gordon, Alexandra J and Qadir, Nida and Chang, Steven Y and Mallow, Christopher and Felzer, Jamie R and Kwon, Jennie H and Exline, Matthew C and Vaughn, Ivana A and Ramesh, Mayur and Papalambros, Leigh and Mosier, Jarrod M and Harris, Estelle S and Baughman, Adrienne and Cornelison, Sydney A and Blair, Paul W and Johnson, Cassandra A and Lewis, Nathaniel M and Ellington, Sascha and Grijalva, Carlos G and Talbot, H Keipp and Casey, Jonathan D and Halasa, Natasha and Chappell, James D and Rutkowski, Rachel E and Ma, Kevin C and Dawood, Fatimah S and Investigating Respiratory Viruses in the Acutely Ill (IVY) Network, Investigating Respiratory Viruses in the Acutely Ill (IVY) Network},
  title = {RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons},
  journal = {JAMA},
  year = {2025},
  volume = {334},
  number = {16},
  pages = {1442},
  doi = {10.1001/jama.2025.15896}
}
Kostenlos starten →